Clinical trials testing combination therapies containing the TLR8-specific agonist motolimod (VTX-2337) for the treatment of various tumor types have been published [215,216,217,218,219,220], and more are currently ongoing or planned (clinicaltrials.gov; NCT03906526, NCT02431559 and NCT04272333). The gene discussed is TLR8; the disease is neoplasm.